Cadrenal Therapeutics Inc. announced the resignation of Robert Lisicki, a Class II Director on the company's board, effective immediately as of July 15, 2025. The company clarified that his departure was not due to any disagreements regarding its operations, policies, or practices. The board will proceed with addressing this change in their upcoming meetings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.